Pasithea

A NEW TECHNOLOGY FOR A THERAPEUTIC APPROACH TO SLEEP APNEA SYNDROME BASED ON NON INVASIVE KINESTHETIC STIMULATION Pasithea's ambition is to develop a new device for the treatment and longitudinal monitoring of sleep apnea. Pasithea is the result of innovative research carried out by two Inserm laboratories (Grenoble and Rennes), 9 patent families and 2 clinical studies on over 100 patients. Pasithea operates in a high-growth market- A chronic disease that is very common and increasingly diagnosed- A poorly tolerated first-line treatment, leaving room for innovative new treatments- Numerous government reimbursement initiatives to monitor patients on a daily basis (Remote Patient Monitoring). Pasithea is a Medtech company developing a breakthrough non invasive technology for the treatment of sleep apnea. The technology is based on the exclusive IP portfolio of AI technologies, physiological sensing and kinesthetic stimulation to treat Obstructive sleep apnea syndrome (OSA) OSA is a common sleep disorder affecting millions of people worldwide. OSA causes fatigue, high blood pressure, and other serious health issues if left untreated. The current standard treatment for OSA is continuous positive airway pressure (CPAP), but it has a high initial refusal rate and a significant dropout rate over time. Other non-CPAP therapies have inconsistent efficacy, highlighting the need for a new and effective approach. Pasithea offers a non-invasive device that treats OSA using kinesthetic stimulation. By delivering controlled startle responses during apneas or hypopneas, the device activates sub-cortical centers that control the muscles in the upper airways, minimizing the number, duration and gravity of respiratory episodes, while preserving sleep structure. Simple to use and effective for all patients.